Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Blood Advances
Journal
Overview
Identity
Overview
Publication Venue For
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report
. 6:2471-2479.
2022
Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
. 6:1371-1380.
2022
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
. 6:1243-1254.
2022
The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question
. 6:679-685.
2022
VpreB surrogate light chain expression in B-lineage ALL: A report from the Children's Oncology Group
. 6:585-589.
2022
Restriction of HIV-1 infection in sickle cell trait
. 5:4922-4934.
2021
Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia
. 5:4727-4740.
2021
Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: A BMTSS-HiGHS2 risk model
. 5:4102-4111.
2021
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
. 5:3748-3759.
2021
American Society of Hematology 2021 guidelines for sickle cell disease: Stem cell transplantation
. 5:3668-3689.
2021
B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations
. 5:3199-3202.
2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
. 5:2775-2787.
2021
Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia
. 5:1474-1482.
2021
Daratumumab plus RVd for newly diagnosed multiple myeloma: Final analysis of the safety run-in cohort of GRIFFIN
. 5:1092-1096.
2021
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia
. 5:504-512.
2021
Acute erythroid leukemia is enriched in NUP98 fusions: A report from the Children's Oncology Group
. 4:6000-6008.
2020
Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura
. 4:5378-5388.
2020
Systems-based hematology: Highlighting successes and next steps
. 4:4574-4583.
2020
Building access to care in adult sickle cell disease: Defining models of care, essential components, and economic aspects
. 4:3804-3813.
2020
American society of hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
. 4:3528-3549.
2020
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
. 4:2245-2253.
2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: A large population-based study in the United States
. 4:2192-2201.
2020
Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease
. 4:2058-2063.
2020
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)
. 4:1683-1689.
2020
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States
. 4:1615-1623.
2020
Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia
. 4:1115-1130.
2020
Clinical and functional significance of circular RNAs in cytogenetically normal AML
. 4:239-251.
2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics
. 4:253-262.
2020
Sex differences in the trajectory of glomerular filtration rate in pediatric and murine sickle cell anemia
. 4:263-265.
2020
Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura
. 3:4177-4186.
2019
American Society of Hematology 2019 guidelines for sickle cell disease: Cardiopulmonary and kidney disease
. 3:3867-3897.
2019
End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settings
. 3:4002-4020.
2019
Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice
. 3:1460-1475.
2019
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
. 3:1939-1949.
2019
Defining the epigenetic status of blood cells using a cyanine-based fluorescent probe for PRMT1
. 2:2829-2836.
2018
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera
. 2:2681-2690.
2018
Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)
. 2:1969-1979.
2018
Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial
. 2:1696-1704.
2018
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission
. 2:1645-1650.
2018
T-cell prolymphocytic leukemia in an adolescent with ataxiatelangiectasia: Novel approach with a JAK3 inhibitor (tofacitinib)
. 1:2724-2728.
2017
Allogeneic bone marrow transplant in the absence of cytoreductive conditioning rescues mice with β-thalassemia major
. 1:2421-2432.
2017
Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma
. 1:2375-2385.
2017
Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States
. 1:282-287.
2017
Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura.
. 1:75-83.
2016
Identity
International Standard Serial Number (issn)
2473-9529
Electronic International Standard Serial Number (eissn)
2473-9537